Results 21 to 30 of about 1,405,949 (200)
A Pilot Cost-Effectiveness Analysis of Treatments in Newly Diagnosed High-Grade Gliomas: The Example of 5-Aminolevulinic Acid Compared With White-Light Surgery [PDF]
, 2015 BACKGROUND: High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse invasion of the normal brain parenchyma. Novel therapies at best prolong survival; their costs are formidable and benefit is marginal.
Alves, M +3 more
core +1 more source
Фармакоэкономика, 2018 The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e.
T. S. Teptsova +5 more
doaj +1 more source
Diseases, 2023 Background: Respiratory syncytial virus (RSV) is one of the leading causes of pediatric hospitalizations, mainly in children under 2 years of age. Hospitalization affects the caregivers’ quality of life (QoL).
August Wrotek +2 more
doaj +1 more source
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis [PDF]
, 2016 UNLABELLED: Prisoners have a high prevalence of hepatitis C virus (HCV), but case-finding may not have been cost-effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness
Brew, Iain F. +10 more
core +3 more sources
HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? [PDF]
, 2014 Background: We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Berkowitz, Bethany K. +11 more
core +19 more sources
A technique for approximating transition rates from published survival analyses
Cost Effectiveness and Resource Allocation, 2019 Background Quality-adjusted-life-years (QALYs) are used to concurrently quantify morbidity and mortality within a single parameter. For this reason, QALYs can facilitate the discussion of risks and benefits during patient counseling regarding treatment ...
Markian A. Pahuta +4 more
doaj +1 more source
BMC Public Health, 2022 Background The burden of chronic diseases is rapidly rising, both in terms of morbidity and mortality. This burden is disproportionally carried by socially disadvantaged population subgroups.
Lisa Van Wilder +6 more
doaj +1 more source
Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer — A Decision-Analysis Model [PDF]
, 1991 BACKGROUND. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy.
Hillner, Bruce E., , M.D. +1 more
core +2 more sources
Measuring Quality-Adjusted Life-Years When Health Fluctuates [PDF]
Value in Health, 2020 Recurrent fluctuations in health states can occur as a result of long-term conditions with episodic symptoms or through side effects of cycles of treatment. Fluctuations and associated duration of symptoms can be predictable (eg, side effects of chemotherapy treatment) or unpredictable (eg, relapse in multiple sclerosis). Such recurrent fluctuations in
Sanghera, Sabina, Coast, Joanna
openaire +4 more sources
Journal of the Formosan Medical Association, 2013 The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho +8 more
doaj +1 more source